Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Equity Ratio (2016 - 2017)

Bone Biologics has reported Equity Ratio over the past 3 years, most recently at 10.55 for Q4 2017.

  • Quarterly Equity Ratio rose 11.54% to 10.55 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 10.55 through Dec 2017, up 11.54% year-over-year, with the annual reading at 10.55 for FY2017, 11.54% up from the prior year.
  • Equity Ratio was 10.55 for Q4 2017 at Bone Biologics, down from 6.1 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.75 in Q1 2016 and troughed at 11.93 in Q4 2016.
  • The 3-year median for Equity Ratio is 6.1 (2017), against an average of 6.57.
  • The largest YoY upside for Equity Ratio was 32.39% in 2017 against a maximum downside of 519.91% in 2017.
  • A 3-year view of Equity Ratio shows it stood at 2.71 in 2015, then plummeted by 339.55% to 11.93 in 2016, then increased by 11.54% to 10.55 in 2017.
  • Per Business Quant, the three most recent readings for BBLG's Equity Ratio are 10.55 (Q4 2017), 6.1 (Q3 2017), and 11.14 (Q2 2017).